BIOA CLASS ACTION NOTICE: BioAge Labs Investors that Suffered Losses are Notified to Contact BFA Law before the March 10 Court Deadline (NASDAQ:BIOA)
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws.
If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Investors have until March 10, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering held on or about September 26, 2024. The case is pending in the U.S. District Court for the Northern District of California and is captioned Soto v. BioAge Labs, Inc., et al., No. 25-cv-196.
Why was BioAge Sued under the Federal Securities Laws?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The Company's lead product candidate, azelaprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed to enhance weight loss.
As alleged, BioAge's IPO documents discussed its ongoing STRIDES Phase 2 trial of azelaprag in combination with GLP-1R agonists for enhanced weight loss. BioAge stated that it was collaborating with Eli Lilly and Company ('Lilly') in connection with STRIDES, and that Lilly would be advising and assisting on all aspects of the trial's design and execution. BioAge also stated that it anticipated topline results in Q3 2025 and discussed the potential for a second Phase 2 clinical trial. As alleged, BioAge's statements conveyed to investors that there were no safety concerns and that it expected top line results to meet its primary endpoint goals.
In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company terminated the trial and ceased further enrollment.
The Stock Declines as the Truth is Revealed
On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The Company stated that the decision to discontinue the STRIDES trial of azelaprag 'became clear' due to 'the emerging safety profile of the current doses tested[.]' This news caused the price of BioAge stock to decline over 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.
Click here for more information: .
What Can You Do?
If you invested in BioAge you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Or contact:
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
18 minutes ago
- Business Upturn
Krispy Kreme, Inc. Class Action: Levi & Korsinsky Reminds Krispy Kreme, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 15, 2025
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Krispy Kreme, Inc. ('Krispy Kreme, Inc.' or the 'Company') (NASDAQ: DNUT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Krispy Kreme, Inc. investors who were adversely affected by alleged securities fraud between February 25, 2025 and May 7, 2025. Follow the link below to get more information and be contacted by a member of our team: Krispy Kreme, Inc. Lawsuit Submission Form DNUT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) demand for Krispy Kreme products declined materially at McDonald's locations after the initial marketing launch; (2) demand at McDonald's locations was a driver of declining average sales per door per week; (3) the partnership with McDonald's was not profitable; (4) the foregoing posed a substantial risk to maintaining the partnership with McDonald's; (5) as a result, the Company would pause expansion into new McDonald's locations; and (6) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. WHAT'S NEXT? If you suffered a loss in Krispy Kreme, Inc. during the relevant time frame, you have until July 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004 [email protected] Tel: (212) 363-7500Fax: (212) 363-7171
Yahoo
21 minutes ago
- Yahoo
As Google AI Takes Over Search, News Sites Lose Clicks and Cut Jobs
Google (NASDAQ:GOOG) is drawing criticism from media executives who say its growing use of artificial intelligence is reducing traffic to news outlets, forcing them to rethink their digital strategies and slash jobs. According to a Wall Street Journal report Tuesday, publishers are reporting major declines in referral traffic as Google's AI Overviews and chatbot features increasingly serve answers directly to users eliminating the need to click on search results. The shift from a search engine to an answer engine is real, said The Atlantic's CEO Nicholas Thompson, who added that media companies now have to explore new approaches to stay relevant. Data from analytics firm Similarweb, cited in the report, shows steep drops in organic search traffic across major publishers: HuffPost's desktop and mobile traffic more than halved in the past three years. The Washington Post saw nearly the same level of decline. Business Insider reported a 55% drop and recently laid off 21% of its workforce. The New York Times saw its share of organic search traffic shrink to 36.5% in April 2025, down from almost 44% in 2022. Although The Wall Street Journal's search traffic rose in raw numbers, its share of total traffic dipped to 24% from 29% over the same period. WaPo CEO William Lewis warned that click-free search answers represent a serious threat to journalism. Beyond news, Google's AI tools have also dented traffic to travel guides, health information, and product review pages. The report notes that Google's upcoming AI Mode could hit even harder. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Here's Why LifeVantage (NASDAQ:LFVN) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad. In contrast to all that, many investors prefer to focus on companies like LifeVantage (NASDAQ:LFVN), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Even modest earnings per share growth (EPS) can create meaningful value, when it is sustained reliably from year to year. So it's easy to see why many investors focus in on EPS growth. Impressively, LifeVantage's EPS catapulted from US$0.29 to US$0.73, over the last year. It's not often a company can achieve year-on-year growth of 154%. One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. The good news is that LifeVantage is growing revenues, and EBIT margins improved by 4.1 percentage points to 5.8%, over the last year. Both of which are great metrics to check off for potential growth. You can take a look at the company's revenue and earnings growth trend, in the chart below. For finer detail, click on the image. See our latest analysis for LifeVantage In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of LifeVantage's forecast profits? It's pleasing to see company leaders with putting their money on the line, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. Shareholders will be pleased by the fact that insiders own LifeVantage shares worth a considerable sum. To be specific, they have US$30m worth of shares. This considerable investment should help drive long-term value in the business. That amounts to 19% of the company, demonstrating a degree of high-level alignment with shareholders. LifeVantage's earnings have taken off in quite an impressive fashion. That sort of growth is nothing short of eye-catching, and the large investment held by insiders should certainly brighten the view of the company. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So based on this quick analysis, we do think it's worth considering LifeVantage for a spot on your watchlist. Of course, just because LifeVantage is growing does not mean it is undervalued. If you're wondering about the valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry. Although LifeVantage certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
